A tumor-targeting peptide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

iRGD Peptide

Item No. 42319

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
cyclic (1→9)-disulfide L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-lysylglycyl-L-prolyl-L-α-aspartyl-L-cysteine
CAS Number
1392278-76-0
Synonyms
  • cyclic[Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys]
  • Internalizing Arginine-Glycine-Aspartic Acid Peptide
Molecular Formula
C35H57N13O14S2
Formula Weight
948.0
Purity
≥95%
Formulation (Request formulation change)
A solid
Peptide Sequence
c[CRGDKGPDC]
Solubility(Learn about Variance in Solubility)
DMSO: Soluble: ≥10 mg/mlPBS (pH 7.2): Soluble: ≥10 mg/ml
SMILES
[H][C@@]12CCCN1C(CNC([C@H](CCCCN)NC([C@H](CC(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC([C@@H](N)CSSC[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC2=O)=O)=O)=O)=O)=O)=O)=O
InChi Code
InChI=1S/C35H57N13O14S2/c36-8-2-1-5-18-30(57)42-14-25(50)48-10-4-7-23(48)33(60)46-21(12-27(53)54)32(59)47-22(34(61)62)16-64-63-15-17(37)28(55)44-19(6-3-9-40-35(38)39)29(56)41-13-24(49)43-20(11-26(51)52)31(58)45-18/h17-23H,1-16,36-37H2,(H,41,56)(H,42,57)(H,43,49)(H,44,55)(H,45,58)(H,46,60)(H,47,59)(H,51,52)(H,53,54)(H,61,62)(H4,38,39,40)/t17-,18-,19-,20-,21-,22-,23-/m0/s1
InChi Key
YHTTWXCDIRTOQX-FQJIPJFPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $125

    Add

    10 mg

    $220

    Add

    25 mg

    $379

    Add
    Cayman Chemical
    Visit Our Lipid Nanoparticle Resource Center for Additional Tools & Resources
    EXPLORE NOW
    Product Description

    Internalizing arginine-glycine-aspartic acid (iRGD) peptide is a tumor-targeting peptide that has been used in the generation of nanocarriers and lipid nanoparticles (LNPs) for the delivery of degraders and anticancer agents in vitro and in vivo.1,2 Nanocarriers composed of zeolitic imidazolate framework 90 (ZIF-90) conjugated to iRGD peptide and encapsulating a fluorescent reporter selectively traffic to tumors over kidneys, lungs, spleen, liver, and heart in mice in an MDA-MB-436 mouse xenograft model. ZIF-90 nanocarriers conjugated to iRGD peptide and encapsulating hemin and atovaquone (Item No. 23802) degrade BTB and CNC homolog 1 (BACH1) in a hemin-dependent manner, reduce the mitochondrial oxygen consumption rate (OCR), and induce cell death in MDA-MB-436 cells.1 The same nanocarriers decrease tumor volume and weight and improve survival in an MDA-MB-436 mouse xenograft model. LNPs conjugated to iRGD peptide and encapsulating mitoxantrone (Item No. 14842) and a pH-responsive 2-(diisopropylamino)ethyl methacrylate (DPA) polymer reduce tumor weight in an MCF-7 breast cancer mouse xenograft model.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lu, L., Liu, G., Lin, C., et al. Mitochondrial metabolism targeted nanoplatform for efficient triple-negative breast cancer combination therapy. Adv. Healthc. Mater. 10(20), e2100978 (2021).

    2. Yao, Y., Saw, P.E., Nie, Y., et al. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy. J. Mater. Chem. B. 7(4), 576-585 (2019).